From: Patient care in rapid-expansion intensive care units during the COVID-19 pandemic crisis
Characteristic | Expansion, N = 66a | Referent, N = 343a | P-value* | q-valueb |
---|---|---|---|---|
Overall—Medications | ||||
 Propofol | 57 (86%) | 212 (62%) |  < 0.001 |  < 0.001 |
 Dexmedetomidine | 50 (76%) | 122 (36%) |  < 0.001 |  < 0.001 |
 Ketamine | 7 (11%) | 10 (2.9%) | 0.011 | 0.032 |
 Vasopressors | 66 (100%) | 325 (95%) | 0.092 | 0.2 |
 Hydroxychloroquine | 1 (92%) | 298 (87%) | 0.2 | 0.3 |
 Remdesivir | 8 (12%) | 45 (13%) | 0.8 |  > 0.9 |
 Tocilizumab | 13 (20%) | 48 (14%) | 0.2 | 0.3 |
 Steroids (any route) | 50 (76%) | 227 (66%) | 0.2 | 0.3 |
Overall—Prone Positioningc | 30 (45%) | 161 (47%) |  > 0.9 |  > 0.9 |
Discharged—Medications | ||||
 Propofol | 46 (85%) | 143 (67%) | 0.015 | 0.044 |
 Dexmedetomidine | 45 (83%) | 90 (42%) |  < 0.001 |  < 0.001 |
 Ketamine | 6 (11%) | 5 (2.3%) | 0.011 | 0.044 |
 Vasopressors | 54 (100%) | 201 (94%) | 0.13 | 0.3 |
 Hydroxychloroquine | 50 (93%) | 188 (88%) | 0.4 | 0.4 |
 Remdesivir | 8 (15%) | 34 (16%) | 0.8 | 0.8 |
 Tocilizumab | 2 (22%) | 32 (15%) | 0.2 | 0.3 |
 Steroids (any route) | 47 (78%) | 144 (68%) | 0.15 | 0.3 |
Discharged—Prone Positioningc | 23 (43%) | 111 (52%) | 0.3 | 0.4 |
Died—Medications | ||||
 Propofol | 11 (92%) | 69 (53%) | 0.023 | 0.2 |
 Dexmedetomidine | 5 (42%) | 32 (25%) | 0.3 | 0.9 |
 Ketamine | 1 (8.3%) | 5 (3.8%) | 0.4 |  > 0.9 |
 Vasopressors | 12 (100%) | 124 (95%) |  > 0.9 |  > 0.9 |
 Hydroxychloroquine | 11 (92%) | 110 (85%) |  > 0.9 |  > 0.9 |
 Remdesivir | 0 (0%) | 11 (8.5%) | 0.6 |  > 0.9 |
 Tocilizumab | 1 (8.3%) | 16 (12%) |  > 0.9 |  > 0.9 |
 Steroids (any route) | 8 (67%) | 83 (64%) |  > 0.9 |  > 0.9 |
Died—Prone Positioningc | 7 (58%) | 50 (38%) | 0.2 | 0.9 |